ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PVLA vs SEPN // RSI-14 & 200D SMA MOMENTUM

Palvella Therapeutics Inc. (NASDAQ) VS. Septerna Inc. (NASDAQ) • 15-METRIC TALLY: PVLA 1 — SEPN 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SEPN
rsi-technicals
62.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PVLA VS. SEPN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PVLA SEPN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.90% -20.70% -7.20 SEPN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -1.14% 5.19% -6.33 SEPN /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.87 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 SEPN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 57.6 62.4 -4.80 SEPN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.11B $2.05B $52.0M PVLA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PVLA REV SEPN REV PVLA GROSS % SEPN GROSS % PVLA FCF SEPN FCF
FY 2025 $108.1M $46.0M — — -$25.0M $109.7M
FY 2024 $39.5M $1.1M — — -$10.8M -$69.6M
FY 2023 $42.8M $151.0K — — -$13.7M -$38.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PVLA // BETA —
SEPN // BETA —